In a move aimed at bolstering the nation’s defenses against Covid-19, the Food and Drug Administration (FDA) has granted emergency use authorization for Novavax’s updated Covid vaccine. Targeted at individuals aged 12 and above, the protein-based vaccine is now set to compete with the mRNA-based offerings from Pfizer and Moderna as the country prepares for a potential resurgence of the virus during the fall and winter months.
The updated vaccine by Novavax is designed to combat the omicron subvariant JN.1, which, although currently a minor player in the Covid landscape, has several offshoots circulating widely in the U.S. Novavax has highlighted the vaccine’s effectiveness against these related strains, emphasizing its broad protective capabilities.
Novavax’s approach relies on a traditional vaccine technology, using proteins to elicit an immune response—a method that has been employed successfully in vaccines against other diseases for decades. This could position Novavax as an attractive option for those hesitant about the newer mRNA technology used by Pfizer and Moderna.
As Novavax gears up for distribution, it anticipates the vaccine will be available in thousands of locations nationwide, including pharmacies and grocery chains. The announcement has already positively impacted Novavax’s market standing, with shares rising more than 8% following the FDA’s decision.
The question remains whether Americans will embrace this new vaccine, especially given the low uptake of booster shots last year, with just 22.5% of adults opting for the latest available doses.
